Nurse Practitioner in Somers, NY Accepting Medicare

8 Nurse Practitioner nurses found. Showing 1 - 8

Mrs. Nicole Michele Cardwell, FNP-BC Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 325 Ny-100, Somers, NY 10589 Phone: 914-669-8289

Miss Eileen Quinones, FNP- Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 340 Route 202, Somers, NY 10589 Phone: 866-589-3110

Mrs. Susan Mcternan, PMH NP-BC Nurse Practitioner - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 29 Carolyn Way, Somers, NY 10589 Phone: 914-562-1731

Mrs. Merin Sanoj Joseph, RN, MSN, FNP- BC Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 189 Route 100, Somers, NY 10589 Phone: 914-232-5101

Mrs. Jane Alice Mcsweeney, CPNP Nurse Practitioner - Pediatrics Medicare: Medicare Enrolled Practice Location: 293 Route 100, 104, Somers, NY 10589 Phone: 914-277-3360    Fax: 914-277-1813

Fay Marie Wright, RN, APRN-BC Nurse Practitioner - Adult Health Medicare: Not Enrolled in Medicare Practice Location: 39 Jean Way, Somers, NY 10589 Phone: 914-672-4231    Fax: 914-277-2243

Mrs. Carol Theodore, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: Colonial Court, 374 Route 116, Somers, NY 10589 Phone: 914-276-0880    Fax: 914-276-0883

Subhanna Asrar-khan, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 325 Routes 100, Somers, NY 10589 Phone: 914-669-8289

News Archive

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

Treatments based on behavioral or non-invasive physiological stimulation show greatest potential

Because the concept of permanent neurological injury has given way to recognition of the brain's potential for long-term regeneration ad reorganization, rehabilitations strategies are undergoing radical changes. The potential for five new translational interventions was examined in an article published ahead of print on November 13 by Neurology Clinical Practice: Barrett AM, Oh-Park M, Chen P, Ifejika NL: Five New Things in Neurorehabilitation.

Ontario nurses look forward to work with Dr. Jeff Turnbull

Registered nurses in Ontario are eager to work with Dr. Jeff Turnbull, the new president of the Canadian Medical Association (CMA), to strengthen our publicly-funded and not-for profit health-care system by improving access, and making it more patient-centred and cost-efficient.

Gem Pharmaceuticals enrolls initial soft tissue sarcoma patients in GPX-150 Phase 2 clinical trial

Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.

Read more Medical News

› Verified 6 days ago